Newsroom

Infected lung cell
News
Bacterial weapons against viral diseases
The COVID-19 pandemic has dramatically demonstrated that the development of effective agents against viral pathogens is of great importance for global health. Although effective vaccines are available for many viral diseases, there is an urgent need for new and effective therapeutic treatments. At the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), the team led by Prof Rolf Müller is researching novel active substances for the treatment of infections. In their latest studies, the researchers were able to identify two new natural product families with promising activity against viruses. Their results have now been published in the journal Angewandte Chemie International Edition.
20.03.2023
HZI Campus
TWINCORE
HIPS
Blutproben
News
What leads to severe COVID-19?
Infection with SARS-CoV-2 leads to severe disease in some people, whereas others do not get ill or only experience mild disease. What causes these differences is not fully understood. It is already known that an overactive innate immune system is causing severe COVID-19 disease, but it is unclear how this is regulated. A team led by Prof Yang Li, Director at the Centre for Individualised Infection Medicine (CiiM) and head of department “Computational Biology for Individualised Medicine” at the Helmholtz Centre for Infection Research (HZI), has come a step closer to answering this question. The researchers addressed the question to what extent the course of disease is genetically or epigenetically regulated. The CiiM is a joint initiative by the HZI and Hannover Medical School (MHH). In addition to Li, the team included other scientists from the HZI and the RESIST cluster of excellence.
23.02.2023
HZI Campus
CiiM
HIRI
Portrait Krause
News
Gérard Krause moves from HZI to WHO
22.02.2023
HZI Campus
TWINCORE
CRC
Fluorescence microscopic image of a zebrafish larva in which neutrophil granulocytes
News
HIPS and CISPA join forces to make future active ingredients safer
In the ImageTox project, the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and the CISPA Helmholtz Center for Information Security are pooling their expertise in the fields of drug discovery and artificial intelligence (AI). Using state-of-the-art machine learning methods, the two Saarbrücken institutes aim to make research into the modes of action of new drugs more efficient. The project is an initiative within the Helmholtz Medical Security, Privacy, and AI Research Center (HMSP), which brings together leading experts from the fields of IT security, data privacy and AI, and medicine to solve pressing medical challenges. ImageTox is funded with 200,000 euros from Helmholtz Imaging, an initiative to promote imaging research.
15.02.2023
HIPS
Illustration Gene
News
When editing bacteria with CRISPR, less is more
Systematically attenuating DNA targeting activity can achieve CRISPR-driven editing in bacteria, greatly boosting colony counts and even increasing the frequency of precise genome editing. This was shown in a study of the Helmholtz Institute Würzburg (HIRI) in collaboration with the Helmholtz Centre for Infection Research (HZI) in Braunschweig. The findings were published today in the journal Nature Communications.
09.02.2023
HZI Campus
HIRI
Fluorescence staining of Arlo cells
News
New cell model for the human lung
Before new drugs can be tested in animal experiments and later in clinical trials, they must undergo a large number of laboratory tests. This involves the use of so-called cell lines, i.e. human or animal cells of a specific tissue that can be cultivated in the laboratory. A team led by Prof Claus-Michael Lehr of the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) has now developed a novel human lung cell line that should enable much more accurate predictions of the behavior of active substances or dosage forms in humans than previous systems. The cell line could be used, among other things, in the development of drugs against SARS-CoV-2. The scientists published their results in the journal Advanced Science.
08.02.2023
HIPS

HZI in the media

KI-Update Deep-Dive: Wie CAIMed Diagnosen verbessern will

Hochschule Hannover, die Universitätsmedizin Göttingen, das Helmholtz-Zentrum für Infektionsforschung in Braunschweig sowie die KI-

07.11.2025
|
Heise online
Vitalpilze – die neuen Wundermittel? Von wegen!

... , Leiter der Forschungsgruppe Mikrobielle Wirkstoffe am Helmholtz-Zentrum für Infektionsforschung, zu bedenken. Das erste ...

07.11.2025
|
Leipziger Volkszeitung (LVZ)
Malaria: Neuer Wirkstoff dreht dem Parasiten den Protein-Hahn zu

Quelle: Pressemitteilung

 

HZI-Helmholtz Zentrum für Infektionsforschung ...

04.11.2025
|
LaborPraxis
Grippe-Schnelltest per Kaugummi

Forschende des Helmholtz-Zentrums für Infektionsforschung und der Universität Würzburg entwickeln derzeit einen Kaugummi, der Grippeviren

04.11.2025
|
Arbeitsmedizin-Sozialmedizin-Umweltmedizin
Eier und Geflügel gefahrlos verzehren? So können sich Menschen vor der Vogelgrippe schützen

... Vakzinologie und angewandte Mikrobiologie am Helmholtz-Zentrum für Infektionsforschung. Die M2-Membranproteinhemmer verhindern ...

02.11.2025
|
Augsburger Allgemeine
Pilze für die Gesundheit – was können „Vitalpilze“?

... etwas dran ist“, erklärt Biologe Marc Stadler vom Helmholtz-Zentrum für Infektionsforschung gegenüber der Barmer-Krankenkasse. „Es ...

30.10.2025
|
bild der wissenschaft
Vaccinated against polio—or not? Study finds differences between documented and self-reported vaccination rates

could be reintroduced at any time. Epidemiologists at the Helmholtz Center for Infection Research (HZI) have now shown that many people do

23.10.2025
|
MSN.com
Gegen Polio Geimpft: Fakten Und Mythen Im Überblick

... eingeschleppt werden könnte. Epidemiolog:innen des Helmholtz-Zentrums für Infektionsforschung (HZI) haben nun gezeigt, dass ...

23.10.2025
|
innovations report
New malaria drug candidate blocks protein production in resistant parasites

this development, a research team at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), in collaboration with the Swiss

22.10.2025
|
Phys.org
Neuer Wirkstoff schneidet Parasiten die Proteinzufuhr ab

Malaria-Medikamentes ermöglichen könnte. Das HIPS ist ein Standort des Helmholtz-Zentrums für Infektionsforschung in Zusammenarbeit mit ...

22.10.2025
|
Verband Deutscher Biologen e.V.
Innovative chemo-enzymatische Methode zur Herstellung von Furanoliden gegen Krebs und Bakterien

(Bild: DOI: 10.1021/jacs.5c08354 / Hips / CC BY 4.0) Wissenschaftler am Hips entwickelten eine Plattform zur Produktion von Furanoliden, die effektiv gegen Bakterien und Krebszellen wirken können und vielversprechende Wirkstoffe darstellen.

21.10.2025
|
PROCESS
Innovative Platform Developed for Producing Versatile Active Ingredients

at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), in partnership with the Helmholtz Centre for Infection Research (HZI

20.10.2025
|
Bioengineer.org

Register now for the HZI-Newsletter